Our study identified two biologically relevant inflammatory mediators in BPS and demonstrated an increase in nociceptive signalling with CCL21. Manipulation of this ligand is a potential new therapeutic strategy for BPS. The gene discussed is CCL21; the disease is Bartsocas-Papas syndrome 1.